| CVALF Stock | | | USD 1.84 0.02 1.10% |
Founder
Dr. Valerio DiTizio serves as a Chief Scientific Officer of Covalon Technologies Ltd., since December 21, 2004. Dr. DiTizio is a coinventor of Covalon technologies and a cofounder of the company. He has degrees in science from the University of Toronto as a Biochemistry Specialist. Dr. DiTizio completed his Master degree in liposome drug delivery. His graduate research involved the application of polymer chemistry and drug delivery in pursuit of novel materials and processes that currently comprise the core of Covalons intellectual property. Dr. DiTizio holds several US and European patents. since 2004.
| Age | 55 |
| Tenure | 21 years |
| Phone | 905 568 8400 |
| Web | https://www.covalon.com |
Covalon Technologies Management Efficiency
The company has return on total asset
(ROA) of
(0.161) % which means that it has lost $0.161 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.3213) %, meaning that it generated substantial loss on money invested by shareholders. Covalon Technologies' management efficiency ratios could be used to measure how well Covalon Technologies manages its routine affairs as well as how well it operates its assets and liabilities.
Covalon Technologies has accumulated 2.25
M in total debt with debt to equity ratio
(D/E) of 0.08, which may suggest the company is not taking enough advantage from borrowing. Covalon Technologies has a current ratio of 9.84, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Covalon Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Covalon Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Covalon Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Covalon to invest in growth at high rates of return. When we think about Covalon Technologies' use of debt, we should always consider it together with cash and equity.
Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. It serves hospitals, wound care centers, burn centers, extendedalternate care and acute care facilities, home health care agencies, and physicians offices. Covalon Tech operates under Biotechnology classification in the United States and is traded on OTC Exchange. Covalon Technologies [CVALF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.
Management Performance
Covalon Technologies Leadership Team
Elected by the shareholders, the Covalon Technologies' board of directors comprises two types of representatives: Covalon Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Covalon. The board's role is to monitor Covalon Technologies' management team and ensure that shareholders' interests are well served. Covalon Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Covalon Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Valerio DiTizio, Co-Founder and Chief Science Officer | |
| Simon Smith, Chief Ltd | |
| Brian Pedlar, CEO and President and Director | |
| Ron Hebert, VP Marketing | |
| Greg Leszczynski, VP HR | |
| Hamed Abbasian, VP Devel | |
| Gerry Arambula, Pres Ltd | |
| Jason Gorel, Interim Officer | |
| Elaine Zhang, VP Operations | |
| Mark Doolittle, VP Sales | |
Covalon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Covalon Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Covalon OTC Stock
Covalon Technologies financial ratios help investors to determine whether Covalon OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Covalon with respect to the benefits of owning Covalon Technologies security.